US 11,950,875 B2
Systems, devices, and methods for integration of an analyte data reader and medication delivery device
Jean-Pierre Cole, Tracy, CA (US); Cherie A. Bulala, Berkeley, CA (US); Theodore J. Kunich, Pleasanton, CA (US); Xuandong Hua, Mountain View, CA (US); and Hila F. Ralston, Alameda, CA (US)
Assigned to ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed by ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed on Apr. 19, 2022, as Appl. No. 17/723,813.
Application 17/723,813 is a continuation of application No. 16/518,691, filed on Jul. 22, 2019, granted, now 11,317,802.
Application 16/518,691 is a continuation of application No. PCT/US2018/018232, filed on Feb. 14, 2018.
Claims priority of provisional application 62/459,441, filed on Feb. 15, 2017.
Prior Publication US 2023/0000350 A1, Jan. 5, 2023
Int. Cl. A61B 5/00 (2006.01); A61B 5/145 (2006.01); A61M 5/14 (2006.01); H01M 10/0525 (2010.01); H04W 4/80 (2018.01)
CPC A61B 5/002 (2013.01) [A61B 5/14532 (2013.01); A61M 5/14 (2013.01); H01M 10/0525 (2013.01); H04W 4/80 (2018.02); A61M 2205/3584 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method for preventing the injection of medication when an adverse condition is present, the method comprising:
detecting an attempt by a user to use a medication delivery device;
receiving, by the medication delivery device, data indicative of an analyte level from a sensor control device configured to be worn by a user;
determining, by the medication delivery device, whether the received data indicative of the analyte level includes recent analyte level data;
determining whether the adverse condition is present based on the received data indicative of the analyte level; and
in response to either a determination that the received data indicative of the analyte level does not include the recent analyte level data, or a determination that the adverse condition is present, activating a lock-out mechanism for a predetermined duration of time and outputting a warning, wherein the lock-out mechanism is configured to prevent use of the medication delivery device, wherein the medication delivery device is an insulin pen, and wherein the lock-out mechanism comprises a latch mechanism configured to prevent activation of the medication delivery device for the predetermined duration of time.